サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791472

抗凝固剤逆転薬の世界市場

Anticoagulant Reversal Drugs

出版日
ページ情報
英文 140 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
抗凝固剤逆転薬の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗凝固剤逆転薬の世界市場は2030年までに30億米ドルに到達

2024年に15億米ドルと推定される抗凝固剤逆転薬の世界市場は、2024～2030年の分析期間中に12.5%のCAGRで成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるイダルシズマブ医薬品は、CAGR 14.8%を記録し、分析期間終了までに18億米ドルに達すると予想されます。フィトナジオン分野の成長率は、分析期間中CAGR 9.6%と推定されます。

米国市場は3億9,170万米ドルと推定、中国はCAGR 11.6%で成長すると予測

米国の抗凝固剤逆転薬市場は、2024年に3億9,170万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,720万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.8％と10.5％と予測されています。欧州では、ドイツがCAGR約8.9％で成長すると予測されています。

抗凝固剤逆転薬市場：動向と今後の軌跡を読み解く

抗凝固剤逆転薬は救急医療をどう変えるか？

抗凝固剤逆転薬は、抗凝固療法により過剰出血を起こした患者への迅速な介入を確実にするため、救急医療やクリティカルケアの現場で不可欠なものとなっています。これらの薬剤は、ワルファリン、ヘパリン、直接経口抗凝固薬（DOAC）などの血液希釈剤の効果を打ち消し、生命を脅かす出血のリスクを低減します。心血管疾患や脳卒中の有病率の上昇により、抗凝固剤の使用が増加しており、その結果、効果的な逆流防止剤の需要が高まっています。新しい抗凝固薬クラスが出現するにつれ、標的を絞った即効性のある逆転薬の必要性はますます重要になっており、この分野は現代医療の重要な構成要素となっています。

この分野の成長を支える主な市場促進要因は何か？

市場拡大の重要な促進要因は、抗凝固療法を必要とする血栓性疾患に罹患しやすい老年人口の増加です。さらに、新規経口抗凝固薬（NOAC）の採用が増加しているため、アンデキサネット・アルファやイダルシズマブのような特殊な逆転薬の開発が必要となっています。画期的治療薬に対する規制当局の支援と迅速な承認が市場の成長をさらに後押しし、救命治療への迅速なアクセスを促進しています。さらに、これらの薬剤の入手可能性と有効性に関する医療従事者の意識の高まりが、世界の採用率の上昇に寄与しています。

技術はどのように逆転薬の開発を促進しているのか？

バイオ医薬品研究の進歩は、抗凝固逆転薬の最適化において極めて重要な役割を果たしています。最先端の遺伝子組換え技術により、副作用を最小限に抑えた、選択性の高い有効な解毒剤の生産が可能になりました。創薬と臨床試験における人工知能（AI）の統合は、抗凝固逆転薬の有望な候補の同定を促進しています。さらに、薬物動態学と標的送達システムの改善により、潜在的な合併症を最小限に抑えながら逆転薬が迅速に作用するようになり、患者の転帰が改善されています。

市場を前進させている要因は何か？

抗凝固剤逆転薬市場の成長は、心血管疾患の有病率の増加、抗凝固薬の使用拡大、医薬品開発技術の進歩など、いくつかの要因によってもたらされています。抗凝固作用の即時回復を必要とする緊急事態の発生率が高まっていることが、主要な触媒となっています。さらに、製薬企業による研究開発投資の増加や、クリティカルケア医薬品へのアクセス改善を目的とした政府の取り組みが、市場の拡大を促進しています。生物製剤や低分子阻害剤の技術革新が進む中、より安全で効率的な逆流防止ソリューションが急務となっており、同市場は大幅な成長を遂げるものと思われます。

セグメント

薬剤クラス（イダルシズマブ製剤、フィトナジオン（ビタミンK）製剤、プロトロンビン複合体濃縮製剤、アンデキサネットアルファ製剤、その他の薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AstraZeneca PLC
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cipla
  • Clearsynth Lab Ltd
  • Dr. Reddy's Laboratories Ltd
  • Eurocrit Labs International
  • Fresenius Kabi Canada Ltd.
  • McKesson Medical-Surgical Inc.
  • Novartis AG
  • Otto Chemie Pvt. Ltd.
  • Pfizer Inc.
  • Shaivya Pharmachem

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29181

Global Anticoagulant Reversal Drugs Market to Reach US$3.0 Billion by 2030

The global market for Anticoagulant Reversal Drugs estimated at US$1.5 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2024-2030. Idarucizumab Drugs, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Phytonadione segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$391.7 Million While China is Forecast to Grow at 11.6% CAGR

The Anticoagulant Reversal Drugs market in the U.S. is estimated at US$391.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.8% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Anticoagulant Reversal Drugs Market: Decoding the Trends and Future Trajectory

How Are Anticoagulant Reversal Drugs Transforming Emergency Medicine?

Anticoagulant reversal drugs have become indispensable in emergency and critical care settings, ensuring swift intervention for patients experiencing excessive bleeding due to anticoagulant therapy. These drugs counteract the effects of blood thinners such as warfarin, heparin, and direct oral anticoagulants (DOACs), reducing the risk of life-threatening hemorrhages. The rising prevalence of cardiovascular diseases and stroke has led to an increased use of anticoagulants, thereby driving demand for effective reversal agents. With newer anticoagulant classes emerging, the need for targeted and faster-acting reversal agents is becoming increasingly crucial, positioning this segment as a key component of modern medical treatment.

What Are the Key Market Drivers Behind the Growth of This Sector?

A significant driver of market expansion is the rising geriatric population, which is more susceptible to thrombotic disorders requiring anticoagulant therapy. Additionally, the growing adoption of novel oral anticoagulants (NOACs) has necessitated the development of specialized reversal drugs like andexanet alfa and idarucizumab. Regulatory support and fast-track approvals for breakthrough therapies further bolster market growth, facilitating quicker access to life-saving treatments. Moreover, increasing awareness among healthcare providers regarding the availability and efficacy of these drugs is contributing to higher adoption rates worldwide.

How Is Technology Enhancing the Development of Reversal Agents?

Advancements in biopharmaceutical research are playing a pivotal role in optimizing anticoagulant reversal agents. Cutting-edge recombinant technology has enabled the production of highly selective and effective antidotes with minimal side effects. The integration of artificial intelligence (AI) in drug discovery and clinical trials is expediting the identification of promising candidates for anticoagulation reversal. Additionally, improvements in pharmacokinetics and targeted delivery systems are ensuring that reversal agents act rapidly while minimizing potential complications, thus improving patient outcomes.

What Factors Are Propelling the Market Forward?

The growth in the anticoagulant reversal drugs market is driven by several factors, including the increasing prevalence of cardiovascular conditions, the expanding use of anticoagulant medications, and advancements in drug development technologies. The growing incidence of emergency situations requiring immediate reversal of anticoagulation effects is a key catalyst. Furthermore, heightened R&D investments by pharmaceutical companies and government initiatives aimed at improving access to critical care drugs are fostering market expansion. With ongoing innovation in biologics and small-molecule inhibitors, the market is set to witness substantial growth, driven by the urgent need for safer and more efficient reversal solutions.

SCOPE OF STUDY:

The report analyzes the Anticoagulant Reversal Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Idarucizumab Drugs, Phytonadione (Vitamin K) Drugs, Prothrombin Complex Concentrate Drugs, Andexanet Alfa Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cipla
  • Clearsynth Lab Ltd
  • Dr. Reddy's Laboratories Ltd
  • Eurocrit Labs International
  • Fresenius Kabi Canada Ltd.
  • McKesson Medical-Surgical Inc.
  • Novartis AG
  • Otto Chemie Pvt. Ltd.
  • Pfizer Inc.
  • Shaivya Pharmachem

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anticoagulant Reversal Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Bleeding Complications in Anticoagulated Patients Driving Demand
    • Expansion of Direct Oral Anticoagulant (DOAC) Reversal Agents Market
    • Increasing Adoption of Targeted Antidotes for Specific Anticoagulants
    • Advancements in Biologic-Based Reversal Agents for Enhanced Efficacy
    • Surge in Demand for Emergency and Hospital-Based Reversal Solutions
    • Growing Investments in Rapid-Acting and Next-Generation Reversal Therapies
    • Expansion of Clinical Trials for New Reversal Drug Candidates
    • Rising Focus on Personalized Medicine and Precision-Based Anticoagulant Reversal
    • Increasing Use of Reversal Agents in Surgical and Trauma Settings
    • Growth in Regulatory Approvals for Novel Anticoagulant Reversal Drugs
    • Surge in Public Awareness and Physician Education on Reversal Drug Applications
    • Increasing Demand for Cost-Effective and Broad-Spectrum Reversal Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anticoagulant Reversal Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Anticoagulant Reversal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Idarucizumab Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Idarucizumab Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phytonadione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phytonadione by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • JAPAN
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • CHINA
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • EUROPE
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • FRANCE
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • GERMANY
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • UNITED KINGDOM
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030

IV. COMPETITION